Some Companies Say 'No' To China's Latest VBP Round

Branded Growth Without Price Cuts Still Possible

Only three of 40 qualified international drug firms won in the latest round of China's central bidding process, showing a toughening environment. But some companies are seemingly determined not to lower prices any further.

Concept of agreement - a man carrying a briefcase walks through a large keyhole
MNCs MOSTLY SAY 'NO' TO LOWERING PRICES IN CHINA'S LATEST VPB ROUND • Source: Shutterstock

In China, there is a saying about falling drug prices for off-patent drugs selected for the country's centralized procurement scheme - “there are only lower bids, no lowest prices.”

But given the results from the latest round of volume-based procurement (VBP), as it formally called, some prices are falling so fast that several

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia